COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #60 of 231
6/17 Late treatment study
Luo et al., Annals of Oncology, 31:10, 1386-1396, doi:10.1016/j.annonc.2020.06.007 (Peer Reviewed)
COVID-19 in patients with lung cancer
Source   PDF   Share   Tweet
Analysis of hospitalized lung cancer patients with 35 of 48 taking HCQ, mortality OR 1.03, p = 0.99.

Luo et al., 6/17/2020, retrospective, USA, North America, peer-reviewed, 31 authors.
risk of death, 2.2% higher, RR 1.02, p = 0.99, treatment 11 of 35 (31.4%), control 4 of 13 (30.8%), odds ratio converted to relative risk.
Details of all 231 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit